# CJC-1295: research reference

For research use only. Checked November 1, 2026.

The CJC-1295 in the cited human studies is a long-acting growth-hormone-releasing hormone analogue designed to bind albumin. Its albumin-binding modification is essential context for interpreting the research. A product labeled “CJC-1295 no DAC” should not inherit those findings simply because it shares part of the name. Exact sequence, terminal chemistry, modification and analytical identity must be established before matching a sample to a paper.

## Identity
Commercial labels can compress chemically important distinctions. This page concerns the albumin-binding CJC-1295 investigated in the cited studies. No-DAC and modified-GRF labels require their own explicit specification; this reference does not certify that every seller uses those names consistently or supplies an interchangeable molecule.

## Mechanism
CJC-1295 was developed as a GHRH analogue with extended residence through covalent albumin binding. The healthy-adult trials examined compound pharmacokinetics alongside growth hormone and IGF-I measurements. This links a defined chemical design to a defined endocrine experiment, not to every later product using the label. [cjc-2006-trials]

A separate investigation evaluated whether growth-hormone pulsatility persisted during the longer stimulus. Its result shows why mean hormone levels and pulse patterns should be distinguished rather than merged into a generic “more physiological” claim. [cjc-2006-pulses]

Chemical persistence, receptor activity and an outcome of interest are separate questions. A long duration in a biological system also says nothing by itself about the stability of a supplied powder or solution.

## Selected research
### Defined long-acting analogue
Model: Randomized, placebo-controlled studies in healthy adults

Investigators reported sustained changes in circulating growth hormone and IGF-I with the albumin-binding material studied.

Limitation: The trials characterized selected pharmacological outcomes and do not validate no-DAC products, blends or broad practical benefits.

### Mean levels versus pulse structure
Model: Hormonal sampling in healthy adult men

Growth-hormone pulsatility persisted while mean and trough hormone measures changed under the experimental conditions.

Limitation: A short, narrowly defined physiological experiment cannot establish long-term outcomes or describe all populations.

## Open questions
- Does the material being evaluated actually carry the albumin-binding modification used in the primary study?
- Which studies address the exact non-DAC analogue, rather than a shared or ambiguously applied name?
- Which longer-term functional outcomes have been investigated separately from hormone concentrations?
- The selected references are not a systematic review or a certification of a product’s regulatory status.

## Storage and handling
Require identity documentation that names the exact analogue and modification. A certificate that repeats only an ambiguous product label leaves the central identification question unresolved.

The cited circulating half-life findings are not storage instructions. No universal shelf life or solution stability period is established by this reference.

For research use only. No schedules, dosing or administration instructions are supplied.

## Sources
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (2006). https://pubmed.ncbi.nlm.nih.gov/16352683/
- Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog (2006). https://pubmed.ncbi.nlm.nih.gov/17018654/

Primary abstracts and metadata checked November 1, 2026. Scope is the albumin-binding analogue, not an asserted synonymy among commercial no-DAC products. Independent scientific review pending.